Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CA2 | P00918 | 8/20 | 0.52 |
| ▸ | MAPK1 | P28482 | 2/20 | 0.52 |
| ▸ | CA1 | P00915 | 6/20 | 0.50 |
| ▸ | SLC1A3 | P43003 | 1/20 | 0.37 |
| ▸ | SLC1A2 | P43004 | 1/20 | 0.37 |
| ▸ | SLC1A1 | P43005 | 1/20 | 0.37 |
| ▸ | USP2 | O75604 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.35 |
| ▸ | FDPS | P14324 | 1/20 | 0.35 |
| ▸ | ACHE | P22303 | 1/20 | 0.35 |
| ▸ | BACE1 | P56817 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | MAPT | P10636 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | ACE2 | Q9BYF1 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL15386604 | 0.79 | CA1 (0.45) | CA2MAPK1CA1SMN1; SMN2TSHR | |
| SCHEMBL26575537 | 0.78 | HDAC1 (0.50) | CA2MAPK1CA1SLC1A3SLC1A2 | |
| SCHEMBL28061879 | 0.76 | CA2 (0.59) | CA2MAPK1CA1SLC1A3SLC1A2 | |
| SCHEMBL27709102 | 0.76 | CA1 (0.50) | CA2MAPK1CA1SMN1; SMN2TSHR | |
| SCHEMBL14285858 | 0.76 | USP2 (0.34) | CA2MAPK1CA1SLC1A3SLC1A2 | |
| SCHEMBL30924819 | 0.75 | CA2 (0.57) | CA2MAPK1CA1SLC1A3SLC1A2 | |
| SCHEMBL28301189 | 0.74 | CA2 (0.47) | CA2MAPK1CA1SLC1A2SLC1A1 | |
| SCHEMBL11751550 | 0.74 | CA1 (0.48) | CA2MAPK1CA1SMN1; SMN2TSHR | |
| SCHEMBL30924792 | 0.74 | CA2 (0.47) | CA2MAPK1CA1SLC1A3SLC1A2 | |
| SCHEMBL515105 | 0.73 | CA2 (0.67) | CA2MAPK1CA1SLC1A3SLC1A2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230331691-A1 | TREPROSTINIL DERIVATIVE COMPOUNDS AND METHODS OF USING SAME | Corsair Pharma, Inc. | 2023-10-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230331691-A1 | TREPROSTINIL DERIVATIVE COMPOUNDS AND METHODS OF USING SAME | PTGIS, PTGIR, PTGER3 | CA2 1086/4885MAPK1 1994/4885CA1 3025/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.